Testing a medicine to prevent low white blood cell counts from chemo
Part of Blood & lymphatic, Cancer, Skin clinical trials.
This trial tests a new way to give a medicine that helps your body make white blood cells after chemotherapy for breast cancer. It may help prevent serious infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with invasive breast cancer.
- You are planning to get certain types of chemotherapy (TAC, TC, or TCbH).
- You are expected to live at least 3 more months.
- You are generally well enough to be up and about (ECOG score 2 or less).
- Your kidney, liver, lung, and blood function are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, Efbemalenograstim Alfa (a type of G-CSF), to prevent a drop in white blood cells (neutropenia) that can happen after chemotherapy combined with immunotherapy. It is for people with advanced lung or esophageal cancer who are at high risk for this complication.
This trial tests if a study drug (Thiopegfilgrastim) can help prevent a dangerous drop in white blood cells (bone marrow suppression) in people with esophageal or lung cancer who are getting chemo and radiation. It may reduce your risk of infection during treatment.
This study tests a new medicine called Telpegfilgrastim to help prevent fever from low white blood cell counts in children (14–17) with certain cancers who are getting strong chemotherapy. It aims to see if the medicine is safe and works well.
This trial tests a medication called efbemalenograstim alfa to help prevent a serious drop in white blood cells (febrile neutropenia) in people with advanced lung cancer who are starting their first round of chemo. It may reduce the risk of infection and other complications.
This study tests whether a medicine called pegfilgrastim can help prevent dangerously low white blood cell counts in women with triple-negative breast cancer receiving a specific chemotherapy combination. Low white blood cells increase infection risk, so this medicine may help patients stay safer during treatment.
This trial compares two drugs (Telpegfilgrastim and Filgrastim) to help prevent dangerously low white blood cell counts after chemotherapy in children and young adults with solid tumors. It's for patients who have already had this problem in a previous chemo round.
Hear when a new Chemotherapy-Induced Febrile Neutropenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.